Oslo, Norway, June 5, 2012
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug
development company, announces that the CEO, Olav Hellebų,
will give a company presentation to investors at Jefferies
2012 Global Healthcare Conference.
The presentation will be made at 4:00 PM EDT (10:00 PM CET)
on Wednesday 6 June 2012.
A Webcast of the presentation will be available at http://wsw.com/webcast/jeff68/clavis/
Contacts:
Olav Hellebų
Chief Executive Officer
+47 24 11 09 50
olav.hellebo@clavispharma.com
Gunnar Manum
Chief Financial Officer
+47 24 11 09 71
+47 95 17 91 90 (mob)
gunnar.manum@clavispharma.com
Mark Swallow / Nina Enegren / David Dible
Citigate Dewe Rogerson
+44 207 282 2948
clavispharma@citigatedr.co.uk
****
About Clavis Pharma
Clavis Pharma ASA is a clinical-stage oncology focused
pharmaceutical company based in Oslo, Norway with a
portfolio of novel anti-cancer drugs in development. These
patented New Chemical Entities (NCEs) are novel, improved
versions of commercially successful drugs, made using
Clavis Pharma's Lipid Vector Technology (LVT)
chemistry. Data generated suggests these potential
breakthrough products may offer improved efficacy and
reduced side effects through enhanced pharmacokinetic
properties, greater tissue penetration, altered metabolism
and, in certain cases, additional modes of action.
Clavis Pharma's has several drug candidates in
development:
-
Elacytarabine, a leukaemia drug, currently in a
randomized, controlled Phase III study in relapsed or
refractory acute myeloid leukaemia;
-
CP-4126, is currently in a pivotal clinical study
compared to gemcitabine for the 1st line treatment of
pancreatic cancer and a Phase II trial for 2nd line
treatment for pancreatic cancer in patients refractory to
1st line gemcitabine treatment;
-
CP-4200, an azacitidine derivative, in preclinical
development for myelodysplastic syndrome (MDS), a disease
that is often a precursor to leukaemia.
Clavis Pharma intends to commercialise its products through
strategic alliances and partnerships with experienced
oncology businesses and, where and when commercially
appropriate, by establishing its own sales and marketing
capabilities.
Recommend:
